<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Tecfidera</title>
	<atom:link href="http://www.tapanray.in/tag/tecfidera/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Utility Model: Would It Work In India For Pharma?</title>
		<link>http://www.tapanray.in/utility-model-would-it-work-in-india-for-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=utility-model-would-it-work-in-india-for-pharma</link>
		<comments>http://www.tapanray.in/utility-model-would-it-work-in-india-for-pharma/#comments</comments>
		<pubDate>Mon, 08 Jun 2015 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Biogen]]></category>
		<category><![CDATA[dimethyl]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[Discussion]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Forward Pharma A/S]]></category>
		<category><![CDATA[fumarate]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[Paper]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section 3d]]></category>
		<category><![CDATA[Tank]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tecfidera]]></category>
		<category><![CDATA[Think]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[Utility]]></category>
		<category><![CDATA[Utility Model]]></category>
		<category><![CDATA[WIPO]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6704</guid>
		<description><![CDATA[The revised draft of India&#8217;s IPR Policy penned by the Government constituted ‘Think-Tank’ in 2014, suggests enactment of new laws, such as for ‘Utility Models’ and Trade Secrets, to fill some gaps in the country&#8217;s IPR ecosystem . However, media reports &#8230; <a href="http://www.tapanray.in/utility-model-would-it-work-in-india-for-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/utility-model-would-it-work-in-india-for-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
